These data and others from the Venclexta clinical development program will be featured in more than 50 abstracts at the 61st
'Venclexta plus anti-CD20 monoclonal antibody-based regimens continue to demonstrate improved long-term outcomes for people with chronic lymphocytic leukemia,' said
The pivotal Phase III CLL14 study evaluated the combination of Venclexta plus Gazyva (obinutuzumab) in people with previously untreated CLL, who had co-existing medical conditions. At a median follow-up of more than three years (39.6 months), when all patients had been off therapy for a minimum of two years, Venclexta plus Gazyva showed high response rates, including MRD-negativity.
Specifically: Higher rates of MRD-negativity in peripheral blood (76 percent vs. 35 percent; p
(C) 2019 Electronic News Publishing, source